Study guide

9.3 Systemic Medication Retinal Toxicity & Plaquenil Screening

IJCAHPO Certified Retina Technician CRT

Track your progress as you read

Finished sections get a check mark.

1 Exam Overview: Current CRT Requirements & Blueprint

Exam Overview: Current Requirements, Scope & Study Plan

2 Chapter 1: History Taking, Triage & Clinical Documentation

1.1 Comprehensive Ophthalmic & Medical History for Retina Patients 1.2 Telephone Triage, Urgent Symptoms & Emergency Scheduling 1.3 Scribing, Electronic Health Records & Retinal Billing Codes

3 Chapter 2: Visual Assessment & Low Vision Rehabilitation

2.1 Standardized Visual Acuity Testing & Optotypes 2.2 Sub-Chart Acuity Protocols: CF, HM, LP, and NLP 2.3 Low Vision Definitions, Optical Devices & Patient Counseling

4 Chapter 3: Pupil Assessment & Visual Field Testing

3.1 Pupillary Examination & Relative Afferent Pupillary Defect 3.2 Confrontation Fields & Automated Perimetry in Retina 3.3 Amsler Grid Testing & Metamorphopsia Monitoring

5 Chapter 4: Tonometry & Ocular Motility

4.1 Goldmann Applanation & Handheld Tonometry Techniques 4.2 Tonometer Disinfection, Calibration & Post-Procedure IOP Monitoring 4.3 Ocular Motility Assessment, Strabismus & Alignment Testing

6 Chapter 5: Diagnostic Ophthalmic Ultrasound

5.1 Ophthalmic B-Scan Echography for Posterior Segment Pathology 5.2 Standardized A-Scan Echography & Optical Biometry

7 Chapter 6: Slit Lamp, Electrophysiology & Supplemental Testing

6.1 Slit Lamp Biomicroscopy, Illumination & Fundus Lenses 6.2 Color Vision Assessment & Hertel Exophthalmometry 6.3 Ophthalmic Electrophysiology: ERG, VEP, and EOG

8 Chapter 7: Ophthalmic Microbiology & Infection Control

7.1 Ocular Pathogens & Routes of Disease Transmission 7.2 Clinical Asepsis, Universal Precautions & Vitreous Specimen Collection

9 Chapter 8: General Retinal Pharmacology & Therapeutics

8.1 Ocular Drug Delivery Methods & Routes of Administration 8.2 Mydriatics, Cycloplegics & Diagnostic Ophthalmic Dyes 8.3 Anesthetics, Glaucoma Agents & Prescription Verification

10 Chapter 9: Anti-VEGF Therapies, Steroids & Retinal Toxicity

9.1 Anti-VEGF Agents & Neovascular Retinal Diseases 9.2 Corticosteroids, Sustained-Release Implants & AREDS Supplements 9.3 Systemic Medication Retinal Toxicity & Plaquenil Screening

11 Chapter 10: Surgical Assisting & Intravitreal Procedures

10.1 Intravitreal Injection Protocol, Antisepsis & Complication Checks 10.2 Retinal Laser Therapy Modalities & Laser Safety Protocols 10.3 Surgical Instrument Handling, Tray Setup & Sterilization

12 Chapter 11: Patient Services, Education & Clinical Care

11.1 Patient Education, Chronic Disease Counseling & Treatment Adherence 11.2 Special Needs Accommodations, Patient Diversity & Interpersonal Skills 11.3 Ophthalmic Emergencies, First Aid & Clinical Care Coordination 11.4 Clinic Operations, Research Support, Forms & Referrals

13 Chapter 12: General Ocular Anatomy & Retinal Physiology

12.1 Ocular Anatomy, Orbit & Posterior Segment Architecture 12.2 Ten Retinal Layers, Photoreceptors & Macular Anatomy 12.3 Ocular Blood Supply, Microcirculation & Vitreoretinal Interface 12.4 Body Systems, Ocular Adnexa & Medical Terminology

14 Chapter 13: Retinal Pathology & Systemic Disease Manifestations

13.1 Age-Related Macular Degeneration & Retinal Vascular Occlusions 13.2 Diabetic Retinopathy & Systemic Diseases Affecting the Retina 13.3 Peripheral Retinal Degenerations, Tears & Detachments

15 Chapter 14: Ophthalmic Optics & Lensometry

14.1 Principles of Ophthalmic Optics & Refraction 14.2 Manual & Automated Lensometry Techniques

16 Chapter 15: Fundus Photography & Ophthalmic Angiography

15.1 Fundus Photography Techniques & Fundus Autofluorescence 15.2 Fluorescein Angiography Principles, Phases & Image Interpretation 15.3 Indocyanine Green Angiography & Angiographic Complication Management

17 Chapter 16: Optical Coherence Tomography (OCT & OCT-A)

16.1 OCT Principles, Scan Acquisition & Artifact Recognition 16.2 Structural OCT Interpretation: Retinal Fluid & Biomarkers 16.3 Optical Coherence Tomography Angiography (OCT-A) Principles & Flow

18 Chapter 17: Equipment Maintenance, Ethics & Regulatory Compliance

17.1 Equipment Maintenance, Calibration Schedules & Clinic Safety 17.2 Medical Ethics, Scope of Practice & Informed Consent 17.3 Patient Privacy, HIPAA Standards & Hazardous Waste Disposal

9.3 Systemic Medication Retinal Toxicity & Plaquenil Screening

Key Takeaways Explain This Topic AI

Current AAO guidance recommends hydroxychloroquine dosing of no more than 5.0 mg/kg/day by real weight; for severely obese patients it also advises keeping the dose at or below 400 mg/day.

Baseline fundus examination, OCT, and fundus autofluorescence should be obtained soon after therapy begins; annual screening with OCT and wide-pattern FAF is recommended while the drug is used, although it may be deferred during the first five years when major risk factors are absent.

Screen both parafoveal and pericentral patterns. Automated visual fields and multifocal ERG are secondary or confirmatory tests when structural results are uncertain or functional corroboration is needed.

Retinopathy can progress after hydroxychloroquine stops, especially when RPE damage is advanced, so suspicious results require reproducible confirmation and prompt clinician communication.

Other systemic medicines can affect the retina or optic pathway; document dose, duration, symptoms, and ordered testing without independently telling a patient to stop medication.

Last updated: September 2026

Systemic Medication Retinal Toxicity

Systemic drugs can injure the neurosensory retina, retinal pigment epithelium, optic nerve, or crystalline deposits. The technician gathers an exact medication history, performs ordered tests reproducibly, and routes suspicious findings to the clinician. A technician does not independently discontinue a systemic medicine; the prescribing and eye-care clinicians balance ocular risk against systemic benefit.

Hydroxychloroquine: current 2025 AAO recommendations

The 2025 American Academy of Ophthalmology revision supersedes the older 2016 framework. Recommended hydroxychloroquine dosing remains no more than 5.0 mg/kg/day using real body weight . For a severely obese patient, the revision additionally advises keeping the daily dose at or below 400 mg . Record the actual prescribed dose, real weight, start date, interruptions, renal disease, and concurrent tamoxifen. Do not use an old cumulative-dose threshold as the primary screening trigger.

Major risk factors include a daily dose above recommendation, long duration, renal impairment, and tamoxifen use. Risk increases with exposure duration, but it is not zero early and cannot be decided from duration alone.

Baseline and annual testing

Obtain a baseline fundus examination, spectral-domain OCT, and fundus autofluorescence soon after treatment starts to document preexisting macular disease and provide comparisons. The current primary screening combination is:

OCT to identify localized photoreceptor, ellipsoid-zone, and outer-retinal change.

Wide-pattern fundus autofluorescence to reveal parafoveal or pericentral RPE stress and damage.

Annual OCT and FAF screening is recommended while hydroxychloroquine is used. In a patient without significant risk factors, the clinician may defer annual screening during the first five years. This is a risk-based decision, not a blanket rule to wait five years.

Automated visual fields and multifocal ERG are secondary or confirmatory tests. A field can corroborate a functional defect but is subjective and must be checked for fixation and reliability. mfERG can objectively map localized dysfunction when structural results are equivocal. Color plates and Amsler grids are not sufficiently sensitive or specific for hydroxychloroquine screening.

Topographic patterns

Look for both parafoveal and pericentral toxicity in every patient. Older guidance often tied pericentral testing mainly to Asian ancestry. Current guidance emphasizes that either pattern can occur across ancestries. Wide-pattern FAF and appropriate OCT scan coverage help avoid missing disease beyond a narrow central field. If a functional field is ordered, the clinician selects a pattern such as 10-2, 24-2C, or wider testing based on the area at risk and available imaging.

A single questionable scan or noisy field should not trigger irreversible action. Repeat acquisition with correct centration, review prior scans, inspect raw B-scans rather than only a color map, and obtain corroboration as ordered. Once toxicity is convincing, the ophthalmologist communicates with the prescribing clinician. Progression may continue after cessation, particularly when RPE damage is already present.

Other systemic retinal toxicities

  • Medication Important pattern Technician focus
  • Tamoxifen Crystalline maculopathy, cavitation, or edema Dose and duration; OCT and acuity as ordered

Pentosan polysulfate Pigmentary maculopathy with dark-adaptation or reading symptoms Lifetime exposure history; FAF and OCT coverage

Thioridazine Dose-related pigmentary retinopathy Medication and dose history; color, field, ERG, and imaging as ordered

Deferoxamine RPE change, pigmentary retinopathy, or optic toxicity Systemic indication, symptoms, and multimodal imaging

  • Vigabatrin Concentric visual-field loss Reliable field testing appropriate to age and ability
  • MEK inhibitors Serous retinopathy-like fluid Baseline symptoms and OCT comparison

Interferon or selected cancer therapies Cotton-wool spots, hemorrhage, vascular or inflammatory effects Exact agent, timing, systemic status, and prompt escalation

Pentosan-associated maculopathy can resemble pattern dystrophy or age-related change. Multimodal imaging and a complete drug history prevent misclassification. Toxicity patterns are not treatment instructions: never advise abrupt cessation, especially when a drug controls autoimmune disease, seizures, cancer, or another serious condition.

Acquisition and documentation checklist

Verify patient and medication name, daily dose, start date, weight, renal history, concurrent risk medicines, and symptoms.

Use the ordered scan pattern and confirm that it covers both central and more peripheral macular risk zones.

Check signal strength, segmentation, centration, fixation, media opacity, and prior-image registration.

Record the test performed and quality limitations; do not label an artifact as toxicity.

Promptly route reproducible or concerning change to the interpreting clinician.

Preserve comparisons and document the handoff.

The safe exam answer distinguishes screening data from clinical diagnosis and uses the current primary tests rather than memorizing superseded rules.

Loading diagram... Current hydroxychloroquine screening logic